Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population.

ABSTRACT:

Introduction

In advanced non-small cell lung cancer (NSCLC), nivolumab plus ipilimumab with platinum-based chemotherapy (NIC) and pembrolizumab with platinum-based chemotherapy (PC) are commonly used treatment options. We conducted a single-center retrospective analysis comparing the two options under real-world conditions in Germany.

Methods

We collected data from patients whose treatment was initiated between July 2018 and June 2023. Primary endpoints were overall survival and safety. Categorical data were compared using the chi-squared test or Fisher's exact test. Overall survival was compared using the Kaplan-Meier method and the log-rank test.

Results

200 patients, 77 treated with NIC and 123 treated with PC, were included. Baseline characteristics were unbalance

SUBMITTER: Weber M 

PROVIDER: S-EPMC12860776 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature